Lazard Asset Management LLC acquired a new stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,922 shares of the biotechnology company’s stock, valued at approximately $45,000.
Several other institutional investors and hedge funds have also recently modified their holdings of ATRA. Nisa Investment Advisors LLC increased its stake in Atara Biotherapeutics by 893.8% during the third quarter. Nisa Investment Advisors LLC now owns 6,460 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 5,810 shares during the period. US Bancorp DE increased its stake in Atara Biotherapeutics by 6,394.9% during the 3rd quarter. US Bancorp DE now owns 7,664 shares of the biotechnology company’s stock worth $29,000 after buying an additional 7,546 shares during the period. First Republic Investment Management Inc. acquired a new stake in Atara Biotherapeutics during the 3rd quarter worth approximately $38,000. Diversified Trust Co purchased a new position in Atara Biotherapeutics in the 3rd quarter valued at approximately $48,000. Finally, Cipher Capital LP acquired a new position in shares of Atara Biotherapeutics in the third quarter worth $49,000.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on ATRA. EF Hutton Acquisition Co. I reiterated a “buy” rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, February 9th. Mizuho reaffirmed a “buy” rating and issued a $31.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, February 7th. Finally, HC Wainwright lowered their price objective on Atara Biotherapeutics from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, February 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $19.25.
Insider Activity
Atara Biotherapeutics Stock Performance
ATRA opened at $3.27 on Wednesday. Atara Biotherapeutics, Inc. has a one year low of $2.83 and a one year high of $10.01. The company has a market cap of $313.68 million, a P/E ratio of -1.47 and a beta of 0.99. The business’s 50-day simple moving average is $4.15 and its 200-day simple moving average is $4.18.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.11). Atara Biotherapeutics had a negative net margin of 359.12% and a negative return on equity of 140.05%. The business had revenue of $0.22 million during the quarter, compared to analyst estimates of $60.00 million. As a group, analysts predict that Atara Biotherapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need.
Featured Articles
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating).
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
